

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2. Immunization Schedule for Persons 18 Years of Age

Type	Recipient Age	Product*	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses†	Doses	Interval Between Doses
mRNA vaccine	18 years and older	MONOVALENT Moderna Red vial cap with a blue-bordered label	Primary series: Monovalent			
			Dose 1 to 2	At least 4–8 weeks‡	Dose 1 to 2	At least 4 weeks
		Dose 2 to 3			At least 4 weeks	
		BIVALENT Moderna Blue cap with gray bordered label	Booster dose: Bivalent			
	Dose 2 to 3		At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
	18 years and older	MONOVALENT Pfizer-BioNTech Gray vial cap with gray-bordered label	Primary series: Monovalent			
Dose 1 to 2			At least 3–8 weeks‡	Dose 1 to 2	At least 3 weeks	
		Dose 2 to 3		At least 4 weeks		
BIVALENT Pfizer-BioNTech: Gray vial cap with gray-bordered label		Booster dose: Bivalent				
	Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)		
Protein subunit vaccine	12 years and older	MONOVALENT Novavax	Primary series: Monovalent			
			Dose 1 to 2	At least 3–8 weeks‡	Dose 1 to 2	At least 3 weeks
		Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.	Booster dose: Bivalent			
			Dose 2 to 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks (2 months)
Adenovirus vector vaccine	18 years and older	MONOVALENT Janssen	Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations. ⁵			
		Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.	Booster dose: Bivalent			
			Administer a single booster dose at least 8 weeks (2 months) after the previous dose.			

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the booster dose, regardless of the primary series product.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA or Novavax COVID-19 Vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

§ For guidance on retrospective record review, scheduling and administration see www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a